|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hoskin P and Dubash S: Bladder
conservation for muscle-invasive bladder cancer. Expert Rev
Anticancer Ther. 12:1015–1020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Y, Hong YK, Zhuang DW, He XJ and Lin
ME: Bladder cancer survival nomogram: Development and validation of
a prediction tool, using the SEER and TCGA databases. Medicine
(Baltimore). 98:e177252019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu P, Zhang G, Zhao J, Chen J, Chen Y,
Huang W, Zhong J and Zeng J: Profiling the urinary microbiota in
male patients with bladder cancer in China. Front Cell Infect
Microbiol. 8:1672018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tzeng HT and Wang YC: Rab-mediated vesicle
trafficking in cancer. J Biomed Sci. 23:702016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Jia Q, Wang Y, Li F, Jia Z and Wan
Y: Rab40b upregulation correlates with the prognosis of gastric
cancer by promoting migration, invasion, and metastasis. Med Oncol.
32:1262015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thomas JD, Zhang YJ, Wei YH, Cho JH,
Morris LE, Wang HY and Zheng XF: Rab1A is an mTORC1 activator and a
colorectal oncogene. Cancer Cell. 26:754–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bin Z, Dedong H, Xiangjie F, Hongwei X and
Qinghui Y: The microRNA-367 inhibits the invasion and metastasis of
gastric cancer by directly repressing Rab23. Genet Test Mol
Biomarkers. 19:69–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang Y, Han Y, Sun C, Han C, Han N, Zhi W
and Qiao Q: Rab23 is overexpressed in human bladder cancer and
promotes cancer cell proliferation and invasion. Tumour Biol.
37:8131–8138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mitra S, Cheng KW and Mills GB: Rab25 in
cancer: A brief update. Biochem Soc Trans. 40:1404–1408. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu G, Niu M, Qin J, Wang Y and Tian J:
Inactivation of Rab27B-dependent signaling pathway by calycosin
inhibits migration and invasion of ER-negative breast cancer cells.
Gene. 709:48–55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo ML, Gong C, Chen CH, Hu H, Huang P,
Zheng M, Yao Y, Wei S, Wulf G, Lieberman J, et al: The Rab2A GTPase
promotes breast cancer stem cells and tumorigenesis via Erk
signaling activation. Cell Rep. 11:111–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Z, Liu XF, Wu HC, Zou SB, Wang JY, Ni
PH, Chen XH and Fan QS: Rab5a overexpression promoting ovarian
cancer cell proliferation may be associated with APPL1-related
epidermal growth factor signaling pathway. Cancer Sci.
101:1454–1462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian K, Jurukovski V, Yuan L, Shan J and
Xu H: WTH3, which encodes a small G protein, is differentially
regulated in multidrug-resistant and sensitive MCF7 cells. Cancer
Res. 65:7421–7428. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuppusamy KT, Sperber H and Ruohola-Baker
H: MicroRNA regulation and role in stem cell maintenance, cardiac
differentiation and hypertrophy. Curr Mol Med. 13:757–764. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li N, Wang L, Tan G, Guo Z, Liu L, Yang M
and He J: MicroRNA-218 inhibits proliferation and invasion in
ovarian cancer by targeting Runx2. Oncotarget. 8:91530–91541. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng XJ, Wu YH, Luo M, Cong PG and Yu H:
Inhibition of pulmonary carcinoma proliferation or metastasis of
miR-218 via down-regulating CDCP1 expression. Eur Rev Med Pharmacol
Sci. 21:1502–1508. 2017.PubMed/NCBI
|
|
19
|
Wang P, Zhai G and Bai Y: Values of
miR-34a and miR-218 expression in the diagnosis of cervical cancer
and the prediction of prognosis. Oncol Lett. 15:3580–3585.
2018.PubMed/NCBI
|
|
20
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama
K, Seki N and Nakagawa M: miR-218 on the genomic loss region of
chromosome 4p15.31 functions as a tumor suppressor in bladder
cancer. Int J Oncol. 39:13–21. 2011.PubMed/NCBI
|
|
21
|
Wang LL, Wang L, Wang XY, Shang D, Yin SJ,
Sun LL and Ji HB: MicroRNA-218 inhibits the proliferation,
migration, and invasion and promotes apoptosis of gastric cancer
cells by targeting LASP1. Tumour Biol. 37:15241–15252. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Sun HH, Sui MH and Ma JJ: miR-218
inhibits acute promyelocytic leukemia cell growth by targeting
BMI-1. Oncol Lett. 14:8078–8083. 2017.PubMed/NCBI
|
|
23
|
Li P, Yang X, Cheng Y, Zhang X, Yang C,
Deng X, Li P, Tao J, Yang H, Wei J, et al: MicroRNA-218 increases
the sensitivity of bladder cancer to cisplatin by targeting Glut1.
Cell Physiol Biochem. 41:921–932. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gulia C, Baldassarra S, Signore F, Rigon
G, Pizzuti V, Gaffi M, Briganti V, Porrello A and Piergentili R:
Role of non-coding RNAs in the etiology of bladder cancer. Genes
(Basel). 8:3392017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Chen L, Ju L, Qian K, Liu X, Wang
X and Xiao Y: Novel biomarkers associated with progression and
prognosis of bladder cancer identified by co-expression analysis.
Front Oncol. 9:10302019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi W, Ochoa A, McConkey DJ, Aine M,
Hoglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L and
Lerner SP: Genetic alterations in the molecular subtypes of bladder
cancer: Illustration in the cancer genome atlas dataset. Eur Urol.
72:354–365. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumar P, Kanaujia SK, Singh A and Pradhan
A: In vivo detection of oral precancer using a fluorescence-based,
in-house-fabricated device: A Mahalanobis distance-based
classification. Lasers Med Sci. 34:1243–1251. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen X, Li J, Li CL and Lu X: Long
non-coding RNA ZFAS1 promotes nasopharyngeal carcinoma through
activation of Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci.
22:3423–3429. 2018.PubMed/NCBI
|
|
30
|
Li Y, Shi B, Dong F, Zhu X, Liu B and Liu
Y: LncRNA KCNQ1OT1 facilitates the progression of bladder cancer by
targeting miR-218-5p/HS3ST3B1. Cancer Gene Ther. 28:212–220. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shan J, Mason JM, Yuan L, Barcia M, Porti
D, Calabro A, Budman D, Vinciguerra V and Xu H: Rab6c, a new member
of the rab gene family, is involved in drug resistance in MCF7/AdrR
cells. Gene. 257:67–75. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bellmunt J, Powles T and Vogelzang NJ: A
review on the evolution of PD-1/PD-L1 immunotherapy for bladder
cancer: The future is now. Cancer Treat Rev. 54:58–67. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong L, Li Y, Xue D and Liu Y: PCMT1 is an
unfavorable predictor and functions as an oncogene in bladder
cancer. IUBMB Life. 70:291–299. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang X, Zhu H, Gao Z, Li J, Zhuang J,
Dong Y, Shen B, Li M, Zhou H, Guo H, et al: Wnt7a activates
canonical Wnt signaling, promotes bladder cancer cell invasion, and
is suppressed by miR-370-3p. J Biol Chem. 293:6693–6706. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roh YG, Mun MH, Jeong MS, Kim WT, Lee SR,
Chung JW, Kim SI, Kim TN, Nam JK and Leem SH: Drug resistance of
bladder cancer cells through activation of ABCG2 by FOXM1. BMB Rep.
51:98–103. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Z, Mao L, Wang L, Zhang H and Hu X:
miR218 functions as a tumor suppressor gene in cervical cancer. Mol
Med Rep. 21:209–219. 2020.PubMed/NCBI
|
|
37
|
Liu T, Zhang X, Du L, Wang Y, Liu X, Tian
H, Wang L, Li P, Zhao Y, Duan W, et al: Exosome-transmitted
miR-128-3p increase chemosensitivity of oxaliplatin-resistant
colorectal cancer. Mol Cancer. 18:432019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xia C, Jiang H, Ye F and Zhuang Z: The
multifunction Of miR-218-5p-Cx43 axis in breast cancer. Onco
Targets Ther. 12:8319–8328. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Setijono SR, Park M, Kim G, Kim Y, Cho KW
and Song SJ: miR-218 and miR-129 regulate breast cancer progression
by targeting Lamins. Biochem Biophys Res Commun. 496:826–833. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu L, Tu H, Liang Y and Tang D: miR-218
produces anti-tumor effects on cervical cancer cells in vitro.
World J Surg Oncol. 16:2042018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao D, Zhang Y, Wang N and Yu N: NEAT1
negatively regulates miR-218 expression and promotes breast cancer
progression. Cancer Biomark. 20:247–254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Deng M, Zeng C, Lu X, He X, Zhang R, Qiu
Q, Zheng G, Jia X, Liu H and He Z: miR-218 suppresses gastric
cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis
in a feedback loop. Cancer Lett. 403:175–185. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang T, Xu L, Jia R and Wei J: miR-218
suppresses the metastasis and EMT of HCC cells via targeting
SERBP1. Acta Biochim Biophys Sin (Shanghai). 49:383–391. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Torres-Berrio A, Nouel D, Cuesta S, Parise
EM, Restrepo-Lozano JM, Larochelle P, Nestler EJ and Flores C:
miR-218: A molecular switch and potential biomarker of
susceptibility to stress. Mol Psychiatry. 25:951–964. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Murray SS, Wong AW, Yang J, Li Y, Putz U,
Tan SS and Howitt J: Ubiquitin regulation of trk receptor
trafficking and degradation. Mol Neurobiol. 56:1628–1636. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xie J, Yan Y, Liu F, Kang H, Xu F, Xiao W,
Wang H and Wang Y: Knockdown of Rab7a suppresses the proliferation,
migration, and xenograft tumor growth of breast cancer cells.
Biosci Rep. 39:BSR201804802019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Černochová R, Nekulová M and Holčaková J:
Rab proteins, intracellular transport and cancer. Klin Onkol. 29
(Suppl 4):S31–S39. 2016.(In Czech). View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fan SJ, Snell C, Turley H, Li JL,
McCormick R, Perera SM, Heublein S, Kazi S, Azad A, Wilson C, et
al: PAT4 levels control amino-acid sensitivity of
rapamycin-resistant mTORC1 from the Golgi and affect clinical
outcome in colorectal cancer. Oncogene. 35:3004–3015. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yin C, Mou Q, Pan X, Zhang G, Li H and Sun
Y: miR-577 suppresses epithelial-mesenchymal transition and
metastasis of breast cancer by targeting Rab25. Thorac Cancer.
9:472–479. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ong ST, Freeley M, Skubis-Zegadlo J, Fazil
MH, Kelleher D, Fresser F, Baier G, Verma NK and Long A:
Phosphorylation of Rab5a protein by protein kinase C is crucial for
T-cell migration. J Biol Chem. 289:19420–19434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tan L, Zhang Y, Zhan Y, Yuan Y, Sun Y, Qiu
X, Meng C, Song C, Liao Y and Ding C: Newcastle disease virus
employs macropinocytosis and Rab5a-dependent intracellular
trafficking to infect DF-1 cells. Oncotarget. 7:86117–86133. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pavarotti M, Capmany A, Vitale N, Colombo
MI and Damiani MT: Rab11 is phosphorylated by classical and novel
protein kinase C isoenzymes upon sustained phorbol ester
activation. Biol Cell. 104:102–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fitzgerald ML and Reed GL: Rab6 is
phosphorylated in thrombin-activated platelets by a protein kinase
C-dependent mechanism: Effects on GTP/GDP binding and cellular
distribution. Biochem J. 342:353–360. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Young J, Menetrey J and Goud B: RAB6C is a
retrogene that encodes a centrosomal protein involved in cell cycle
progression. J Mol Biol. 397:69–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fohlin H, Bekkhus T, Sandström J,
Fornander T, Nordenskjöld B, Carstensen J and Stål O: RAB6C is an
independent prognostic factor of estrogen
receptor-positive/progesterone receptor-negative breast cancer.
Oncol Lett. 19:52–60. 2020.PubMed/NCBI
|
